These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22878559)

  • 1. Mutual influence of backbone proline substitution and lipophilic tail character on the biological activity of simplified analogues of caspofungin.
    Mulder MP; Fodran P; Kemmink J; Breukink EJ; Kruijtzer JA; Minnaard AJ; Liskamp RM
    Org Biomol Chem; 2012 Oct; 10(37):7491-502. PubMed ID: 22878559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of novel macrocyclic antifungal peptides.
    Mulder MP; Kruijtzer JA; Breukink EJ; Kemmink J; Pieters RJ; Liskamp RM
    Bioorg Med Chem; 2011 Nov; 19(21):6505-17. PubMed ID: 21940175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and antifungal evaluation of pentyloxyl-diphenylisoxazoloyl pneumocandins and echinocandins.
    Singh SB; Herath K; Kahn JN; Mann P; Abruzzo G; Motyl M
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3253-6. PubMed ID: 23623416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antifungal activities of glycosylated derivatives of the cyclic peptide fungicide caspofungin.
    Guo J; Hu H; Zhao Q; Wang T; Zou Y; Yu S; Wu Q; Guo Z
    ChemMedChem; 2012 Aug; 7(8):1496-503. PubMed ID: 22684908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition.
    Morikawa H; Tomishima M; Kayakiri N; Araki T; Barrett D; Akamatsu S; Matsumoto S; Uchida S; Nakai T; Takeda S; Maki K
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1172-5. PubMed ID: 24468413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic colisporifungin and linear cavinafungins, antifungal lipopeptides isolated from Colispora cavincola.
    Ortíz-López FJ; Monteiro MC; González-Menéndez V; Tormo JR; Genilloud O; Bills GF; Vicente F; Zhang C; Roemer T; Singh SB; Reyes F
    J Nat Prod; 2015 Mar; 78(3):468-75. PubMed ID: 25636062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.
    García-Agudo L; García-Martos P; Martos-Cañadas J; Aznar-Marín P; Marín-Casanova P; Rodríguez-Iglesias M
    Rev Esp Quimioter; 2012 Dec; 25(4):256-60. PubMed ID: 23303256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of resistance to amphotericin B and caspofungin in Candida spp.: experimental study.
    Soler L; Pastor E; Rodriguez JC; Ruiz M; Lopez P; Cremades R; Royo G
    J Chemother; 2009 Aug; 21(4):467-9. PubMed ID: 19622473
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of killing activity of caspofungin against Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis.
    Varga I; Sóczó G; Kardos G; Borbély A; Szabó Z; Kemény-Beke A; Majoros L
    J Antimicrob Chemother; 2008 Dec; 62(6):1466-8. PubMed ID: 18824459
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
    Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
    Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal inhibitory concentration (MIC) of caspofungin and itraconazole inhibiting growth of Candida strains calculated from the linear regression equation.
    Kurnatowska A; Kurnatowski P; Horwatt-Bożyczko E; Kurnatowska AJ
    Adv Med Sci; 2012 Jun; 57(1):148-51. PubMed ID: 22543256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caspofungin infusion solutions (50 mg/100 mL): chemical stability and antifungal activity against Candida spp.
    Pinder N; Pelzl LH; Walther G; Backhaus J; Kurzai O; Hoppe-Tichy T
    Pharmazie; 2017 Apr; 72(4):197-199. PubMed ID: 29441986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echinocandins - structure, mechanism of action and use in antifungal therapy.
    Szymański M; Chmielewska S; Czyżewska U; Malinowska M; Tylicki A
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):876-894. PubMed ID: 35296203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of caspofungin and voriconazole against uncommon Candida spp.
    Enache-Angoulvant A; Girard A; Poirot JL; Hennequin C
    Int J Antimicrob Agents; 2009 Jun; 33(6):595-6. PubMed ID: 19162450
    [No Abstract]   [Full Text] [Related]  

  • 15. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms.
    Cocuaud C; Rodier MH; Daniault G; Imbert C
    J Antimicrob Chemother; 2005 Sep; 56(3):507-12. PubMed ID: 16040622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration.
    Majoros L; Kardos G; Szabó B; Sipiczki M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3486-8. PubMed ID: 16048965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The echinocandin caspofungin impairs the innate immune mechanism against Candida parapsilosis.
    van Asbeck EC; Hoepelman AI; Scharringa J; Verhoef J
    Int J Antimicrob Agents; 2009 Jan; 33(1):21-6. PubMed ID: 18774697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species.
    Serefko A; Los R; Biernasiuk A; Malm A
    New Microbiol; 2008 Apr; 31(2):257-62. PubMed ID: 18623992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.
    Cota J; Carden M; Graybill JR; Najvar LK; Burgess DS; Wiederhold NP
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3926-8. PubMed ID: 16940061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.